PUMA
PUMA Ambassadors and World Champions Karsten Warholm and Magnus Carlsen challenge themselves by entering each other’s worlds. In an interview with Sports company PUMA, the Norwegian athletes speak about how they started training and competing in Track & Field and Chess, pointing out the importance of having fun while doing sport.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220419005682/en/
“It all starts with just having fun with whatever it is that you have an offer to go to,” Karsten says. “For me, it was all about meeting up with friends. That's what made me always come back.” Magnus also reflects on his experience, “I started specializing immediately when I was eight years old, but I didn't think about it that way. I would do chess all the time, not because somebody told me to, but because I loved it.”
The World Chess Champion Magnus Carlsen and the 400m hurdles Olympic Champion Karsten Warholm discuss competitiveness and how they reached the highest level in their disciplines. “I think at some point you start competing against yourself,” Magnus says. “If I win a game and I didn’t perform well, I'm not going to be happy.”
“Somebody just enjoys winning and somebody just hates losing. When I win, that is somehow what I expect of myself. I think if you're not competitive, you are not able to make it on the highest level,” Karsten explained.
Since both achieved great goals in their sports, they speak about the best moment in their careers. Karsten has no doubts: Tokyo 2021 and his World Record at the Olympic Games. For Magnus, the Norwegian Chess Championship (under 11) in 2000 is something that he will never forget, because it was the first time he was ever the best.
Karsten and Magnus share the same Norwegian roots and they agree on why they feel that being part of the PUMA family is the best fit for them.
Photographer: Olav Stubberud
Videographer: Bjørnar Verpeide
Glam & Styling: Charlotte Wold
PUMA
PUMA is one of the world’s leading sports brands, designing, developing, selling and marketing footwear, apparel and accessories. For more than 70 years, PUMA has relentlessly pushed sport and culture forward by creating fast products for the world’s fastest athletes. PUMA offers performance and sport-inspired lifestyle products in categories such as Football, Running and Training, Basketball, Golf, and Motorsports. It collaborates with renowned designers and brands to bring sport influences into street culture and fashion. The PUMA Group owns the brands PUMA, Cobra Golf and stichd. The company distributes its products in more than 120 countries, employs about 16,000 people worldwide, and is headquartered in Herzogenaurach/Germany.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220419005682/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AGC Biologics Partners with Rarity PBC to Advance Life-Saving Gene Therapy for "Bubble Baby Disease"23.10.2025 09:00:00 CEST | Press release
Collaboration will leverage AGC Biologics’ commercial manufacturing experience and proven platforms to seek regulatory approval for a therapy treating the rare immunodeficiency disorder, ADA-SCID. AGC Biologics, your friendly CDMO expert, today announced an agreement with Rarity PBC to provide comprehensive development and Good Manufacturing Practice (GMP) manufacturing for Rarity's gene therapy, RDP-101, for Adenosine Deaminase Severe Combined Immunodeficiency Disorder. If approved by the U.S. Food and Drug Administration, RDP-101 would be the first gene therapy available for commercial use to reverse ADA-SCID in patients within the United States. ADA-SCID is a rare, life-threatening inherited condition that severely compromises the immune system, leaving infants vulnerable to frequent and severe infections. For every million babies born worldwide, it is estimated that between one and five will have this condition. The ADA-SCID disorder caused by an Adenosine Deaminase deficiency is f
TOURISE and Globant Unveil Game-Changing Report on Agentic Tourism that Sets New Standards for AI-Driven Destination Innovation23.10.2025 08:01:00 CEST | Press release
Imagine a traveler’s perfect day planning itself, rerouting around a rainstorm, prompting a café to add staff before the lunch rush, suggesting a quiet gallery when crowds swell. This is the promise of Agentic Tourism, an AI-powered operating model introduced in a new white paper by TOURISE and Globant, a digitally native company that helps organizations thrive in a digital and AI-powered future, with strategic contribution from Kearney. The report, titled Tourism’s AI Takeover: Reinventing Travel through Agentic Tourism, presents a practical framework for transforming the tourism experience making it more seamless, intelligent, and emotionally resonant. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022347041/en/ TOURISE and Globant Unveil New White Paper on Agentic AI in Tourism In 2024, tourism generated 10.9 trillion dollars, nearly 10 percent of global GDP, and is projected to reach 16.5 trillion dollars by 2035. AI
Bureau Veritas:Robust and Consistent Revenue Performance Delivered in Q3 2025; FY 2025 Outlook Reaffirmed23.10.2025 07:30:00 CEST | Press release
Bureau Veritas (BOURSE:BVI): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022995674/en/ Hinda Gharbi, CEO Bureau Veritas Q3 2025 Key figures1 › Revenue of EUR 1,583.7 million, up 2.3% year-on-year and up 6.3% organically › A very strong organic growth from Marine & Offshore at 16.2%; solid recovery of Buildings & Infrastructure at 7.1% organically; strong organic growth maintained for both Industry and Certification, at 6.9% and 5.9% respectively, against challenging comparables; moderate organic growth for Consumer Products Services at 3.5% and Agri-Food & Commodities at 2.5% › Positive scope effect of 0.8%, from the accelerated pace of bolt-on acquisitions (+3.1% contribution) realized, net of disposals (-2.3% contribution) › Negative currency impact of 4.8%, resulting from the euro’s appreciation against most currencies Q3 2025 Highlights › Continued progress in implementing the LEAP I 28 strategy, delivering results
Bureau Veritas Accelerating Its LEAP | 28 Strategy With Two Signed Agreements for Acquisitions in Buildings & Infrastructure and Renewables23.10.2025 07:20:00 CEST | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification (TIC) services, announces that it has signed agreements to acquire two companies in Europe, reinforcing its leading position and expanding into high-potential markets: Sólida in the renewables sector, and London Building Control in the Buildings & Infrastructure market. These agreements underscore Bureau Veritas’ commitment to growth within its LEAP I 28 strategy, increasing capability, reach, and technical expertise across growth markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022071543/en/ Hinda Gharbi, CEO Bureau Veritas Sólida is a top-tier provider of Owner’s Engineering, Technical Advisory, and Project Management services for renewable energy projects and electrical infrastructure. It acts as a trusted technical partner for leading developers, utilities, EPC contractors, investment funds and financial institutions. The Company has demo
Galderma Delivers Record Net Sales of 3.737 Billion USD in the First Nine Months of 2025 and 15.0% Year-on-Year Growth at Constant Currency, Raises Full-Year Guidance23.10.2025 07:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the first nine months of 2025, delivering record net sales along with strong commercial and innovation momentum across its portfolio. Record net sales of 3.737 billion USD for the first nine months of the year, representing net sales growth of 15.0% at constant currency1, despite challenging market dynamics, driven primarily by volume growth complemented by favorable mix Widespread growth with acceleration across all geographies and product categories, including Injectable Aesthetics (+10.5%) with some phasing benefits in Neuromodulators, Dermatological Skincare (+8.2%), and Therapeutic Dermatology (+40.4%), all year-on-year for the first nine months of 2025 at constant currency Advancing future growth drivers across the portfolio, led by the strong commercial momentum of Nemluvio® as well as the ramp-up of multiple launches in fl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom